Mortality from COVID-19 in patients with lung cancer
Journal of Cancer Metastasis and Treatment
; 7 (no pagination), 2021.
Artículo
en Inglés
| EMBASE | ID: covidwho-2324250
ABSTRACT
The World Health Organization declared coronavirus infectious disease-2019 (COVID-19) linked to the severe acute respiratory syndrome (SARS-CoV-2), a global pandemic in March 2020. The pandemic outbreak has led to the most unprecedented and catastrophic loss of human life in the recent history. As of January 2021, there were more than 100 million cases of COVID-19 and more than two million deaths worldwide. Compared to the general population, patients with cancer are at a higher risk of poor outcomes from COVID-19. In large cohort studies, mortality from COVID-19 in patients with cancer can be as high as 40%. In addition to clinical variables (older age, male sex, and co-morbidities) that are associated with mortality in general population, cancer patients are uniquely vulnerable to severe COVID-19 due to immunosuppression from cancer and its therapy, and disruption of routine clinical care. Among patients with cancer, the lung cancer population is at a higher risk of poor outcomes and mortality from COVID-19 for several reasons. For instance, lung is the main target organ in COVID-19 that can lead to respiratory failure, patients with lung cancer have baseline poor lung function from chronic obstructive pulmonary disorder and smoking. In addition, some of the lung cancer treatment side-effects like pneumonitis, may obscure the diagnosis of COVID-19. In this article, we systematically review the most impactful cohort studies published to date in patients with cancer and COVID-19. We describe the rates of mortality in patients with cancer and COVID-19 with a special focus on the lung cancer population. We also summarize the factors associated with poor outcomes and mortality in patients with lung cancer and COVID-19.Copyright © The Author(s) 2021.
Coronavirus; covid-19; Lung cancer; Mortality; all cause mortality; cancer chemotherapy; cancer immunotherapy; cancer patient; cohort analysis; comorbidity; coronavirus disease 2019/di [Diagnosis]; coronavirus disease 2019/dt [Drug Therapy]; high risk patient; human; hypertension; laboratory test; lung cancer/dt [Drug Therapy]; lung cancer/ep [Epidemiology]; mortality rate; multivariate analysis; non small cell lung cancer/ep [Epidemiology]; pandemic; priority journal; review; Severe acute respiratory syndrome coronavirus 2; sex difference; smoking; steroid therapy; azithromycin/cb [Drug Combination]; azithromycin/dt [Drug Therapy]; cytotoxic agent/dt [Drug Therapy]; D dimer/ec [Endogenous Compound]; hydroxychloroquine/cb [Drug Combination]; hydroxychloroquine/dt [Drug Therapy]; lactate dehydrogenase/ec [Endogenous Compound]; lactic acid/ec [Endogenous Compound]; steroid/dt [Drug Therapy]
Texto completo:
Disponible
Colección:
Bases de datos de organismos internacionales
Base de datos:
EMBASE
Tipo de estudio:
Estudio de cohorte
/
Estudio observacional
/
Estudio pronóstico
Idioma:
Inglés
Revista:
Journal of Cancer Metastasis and Treatment
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS